Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.</li>
<li>The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.</li>
<li>The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.</li>
</ul>


Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.
The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.
The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.


Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth